Draconis Pharma is a company mainly focused on the research of immunological response and the new therapies for the treatment of immune-based diseases such as inflammation, autoimmunity, allergy and related diseases (cancer, pain, etc). Draconis offers experimental services in the early stages of discovery and pre-clinical research to pharmaceutical, biotechnological and food companies. Draconis’ scientific expertise guarantees highly customized solutions to evaluate, the efficacy, safety and toxicology of many types of compounds, such as small molecules, proteins, antibodies, RNA-based compounds, vaccines, functional foods or probiotics, in a wide range of target and disease experimental models. Draconis has developed an own pipeline as a result of its R&D collaborations.